• Mirna Therapeutics Inc., of Austin, Texas, has initiated a Phase I study of MRX34, the first miRNA to advance to a clinical trial for cancer. The trial is being conducted in patients with unresectable primary liver cancer or metastatic cancer with liver involvement.